When you see positive treatment results, John sees a chance to roast more marshmallows.
Confidence in choosing the right cancer treatment for your patient comes from seeing results. Experience and data have shown ERBITUX use in appropriate patients can deliver the real, tangible results you need to see. Because when you see results, your patient sees hope.
Rediscover an established treatment option, previously approved for the treatment of KRAS WT mCRC, now available as combination treatment for BRAF V600E mutant (MT) mCRC.
Select tumor type to see efficacy and safety data from phase III trials evaluating ERBITUX.